| Title |
Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, July 2011
|
| DOI | 10.2147/tcrm.s23036 |
| Pubmed ID | |
| Authors |
Patrick Lemoine, Doron Garfinkel, Moshe Laudon, Tali Nir, Nava Zisapel |
| Abstract |
Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month efficacy and safety of PRM in insomnia patients aged 18-80 and lack of withdrawal and rebound symptoms upon discontinuation. |
X Demographics
The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 21% |
| Spain | 6 | 21% |
| Comoros | 1 | 4% |
| Germany | 1 | 4% |
| Saudi Arabia | 1 | 4% |
| Brazil | 1 | 4% |
| Peru | 1 | 4% |
| Venezuela, Bolivarian Republic of | 1 | 4% |
| Malaysia | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 71% |
| Practitioners (doctors, other healthcare professionals) | 7 | 25% |
| Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Bachelor | 4 | 8% |
| Student > Doctoral Student | 4 | 8% |
| Professor > Associate Professor | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 12 | 25% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Agricultural and Biological Sciences | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Psychology | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 18 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2024.
All research outputs
#1,070,098
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#41
of 1,323 outputs
Outputs of similar age
#4,261
of 127,138 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 11 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 127,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.